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ABSTRACT:
The purpose of this study was to develop and validate limited-
sampling strategies for prediction of the area under the plasma-
concentration time curves (AUCs) of the lactone and total (i.e.,
lactone plus carboxylate) forms of the novel topoisomerase-I in-
hibitor 9-amino-20(S)-camptothecin (9-AC). Complete pharmaco-
kinetic curves for both drug species were obtained from 32 pa-
tients who received the drug orally in a clinical phase I setting at
dose levels ranging from 0.25 to 1.10 mg/m2. The concentrations of
the lactone and carboxylate forms of 9-AC in plasma were mea-
sured by HPLC. Using data from 20 randomly selected patients,
forward-stepwise multivariate regression analysis was used to
generate modeling strategies incorporating data from one, two, or
three plasma samples. The simultaneous optimal prediction of
both 9-AC lactone and 9-AC total AUCs was obtained with sample
time points at 0.33, 3.0, and 11.0 h after drug dosing. Validation of
the models on an independent data set comprising data of the
remaining 12 patients demonstrated that 9-AC lactone and 9-AC
total AUCs could be predicted sufficiently unbiased and precise
using one and two time points: [AUC (ng z h/ml) 5 7.103*C3 1 4.333]
for 9-AC lactone and [AUC (ng z h/ml) 5 9.612*C3 1 13.77*C11 2
44.11] for 9-AC total, where C3 and C11 represent the 9-AC plasma
concentrations in ng/ml at 3 and 11 h after drug dosing. Application
of the proposed models will be valuable in the determination of
9-AC population pharmacokinetics and permits treatment optimi-
zation for patients on the basis of individual pharmacokinetic char-
acteristics through restricted drug monitoring in clinical routines.
9-Amino-20(S)-camptothecin (9-AC; NSC 603071)1 is a synthetic
derivative of the cytotoxic plant alkaloid camptothecin that does not
produce hemorrhagic cystitis associated with the parent compound
(Potmesil, 1994; Takimoto and Arbuck, 1996; Gerrits et al., 1997).
The mechanism of action of 9-AC involves stabilization of a cleavable
complex between the intranuclear enzyme topoisomerase-I and DNA,
thereby inhibiting resealing of enzyme-mediated single-strand breaks
required for DNA replication and RNA transcription (Hsiang et al.,
1985, 1989; Hertzberg et al., 1989a). In preclinical studies, complete
remissions have been obtained with 9-AC in nude mice bearing
human tumor xenografts resistant to common antineoplastic agents
(Giovanella et al., 1989, 1991; Pantazis et al., 1992, 1993). These
animal studies further demonstrated that a prolonged duration of
exposure and a higher frequency of administration were necessary to
maximize drug efficacy.
Although many schedules of drug administration for camptothecin
analogs have been evaluated (reviewed in Creemers et al., 1994;
Gerrits et al., 1997), the optimal schedule and route of administration
of 9-AC have not yet been defined. Based on favorable results of
preclinical studies of 9-AC in mice given on an intermittent protracted
intragastric or oral schedule (Potmesil et al., 1995; Pastori et al., 1997;
De Souza et al., 1997) and our observation of significant intestinal
absorption of the drug in patients (Sparreboom et al., 1998), we
recently performed a clinical phase I study of oral 9-AC in a daily-
times-fourteen schedule (De Jonge et al., 1999a). The dose-limiting
myelotoxicity in that study was demonstrated to be significantly
correlated with the area under the plasma concentration-time curve
(AUC) of the closed lactone form of 9-AC, which suggests that
kinetic-dynamic relationships of the drug may be important for future
dosing strategies (De Jonge et al., 1999b). In addition, we have shown
that 9-AC delineates dose-independent pharmacokinetics with sub-
stantial interindividual differences in the maximum plasma concen-
tration (Cmax) as well as in the AUC with both i.v. and oral drug
administration (De Jonge et al., 1999b), further indicating that tailor-
ing 9-AC dosage to a patient’s individual needs could be of crucial
importance. Accurate estimation of the AUC of 9-AC, however,
requires analysis of 9 to 12 samples after drug administration, which
is in general considered inconvenient and expensive. In view of these
problems inherent to the drug, it was the aim of the present report to
investigate the utility of limited-sampling strategies for prediction of
the systemic exposure to oral 9-AC. These strategies would eventually
enable estimation of the risk of hematological toxicity and/or conve-
nient use of adaptive controlled dosing, using a limited number of
samples drawn on the first day of oral 9-AC chemotherapy.
1 Abbreviations used are: 9-AC, 9-amino-20(S)-camptothecin; AUC, area un-
der the plasma concentration-time curve; Cmax, maximum plasma concentration;
%MPE, percent mean predictive error; %RMSE, percent root mean-squared
predictive error.
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Materials and Methods
Patients and Treatment. The pharmacokinetic models were developed and
validated in 32 patients with a histologically or cytologically proven malignant
solid tumor that participated in a phase I and pharmacokinetic evaluation of
9-AC given in a repeated oral schedule (De Jonge et al., 1999a). Eligibility
criteria included the following: 1) age between 18 and 75 years; 2) an Eastern
Cooperative Oncology Group (ECOG) performance status ,2; 3) life expec-
tancy of at least 12 weeks; 4) adequate hematopoietic (absolute peripheral
granulocyte count .2000 ml21 and platelets .100,000 ml21), hepatic (total
bilirubin within normal limits and aspartate aminotransferase, alanine amino-
transferase, and alkaline phosphatase ,2 times upper normal limits), and renal
functions (creatinine: ,133 mM); and 5) provision of informed written consent
according to guidelines of the institutional review board before treatment.
9-AC was provided by Pharmacia & Upjohn (Milan, Italy) as hard gelatin
capsules in a matrix containing PEG1000 as excipient (see Sparreboom et al.,
1998 for descriptive characteristics of the dosage form). The drug was given
with 150 to 200 ml of water by single-daily oral administration for 14 days at
0.25 mg/m2 (n 5 8), 0.40 (n 5 3), 0.60 (n 5 3), 0.84 (n 5 7), 1.0 (n 5 7), or
1.1 mg/m2 (n 5 3). Treatment cycles were repeated every 21 days, and all
patients had fasted at least 8 h before and 0.5 h after 9-AC administration.
Pharmacokinetic Analysis. Blood sampling for 9-AC pharmacokinetic
analysis was performed on day 1 of the first chemotherapy course, making 32
pharmacologic data sets evaluable for analysis. Heparinized blood samples
were drawn from an indwelling cannula at 0 (predose), 0.33, 0.66, 1, 2, 3, 5,
7.5, 11, and 24 h (Fig. 1) after dosing. Determination of 9-AC lactone and
9-AC total (i.e., lactone plus carboxylate) plasma concentrations was per-
formed by reversed-phase HPLC with fluorescence detection as described in
detail previously (Loos et al., 1997). The lower limits of quantitation using
1-ml samples were 50 and 100 pg/ml for the lactone and total forms, respec-
tively, with the percent deviation (accuracy) and precision of the assay always
being less than 10%.
Individual 9-AC lactone concentration-time data were fitted to a triexpo-
nential equation after extravascular bolus with lag time using the Powell-
minimization algorithm and weighted (1/y) least-squares regression analysis,
using Siphar v4.0 (Simed, Creteil, France) as described (Sparreboom et al.,
1998). The AUC for 9-AC total from time zero to the last measurable level
(Clast) was calculated by the trapezoidal rule. Extrapolation to infinity was
obtained by dividing Clast by the elimination rate constant (kel), estimated by a
log-linear fit of the terminal phase. The terminal elimination half-life [T1/2(g)]
was estimated by ln2/kel. Cmax was estimated by visual inspection of the
semilogarithmic plot of the concentration-time curve. Interpatient and intrapa-
tient variability in pharmacokinetic parameters was assessed by the coefficient
of variation, expressed as the ratio of the standard deviation and the observed
mean. Pharmacokinetic parameters were Gaussian distributed as judged by
normality plots and the Kolmogorov-Smirnov test.
Model Development and Validation. Limited-sampling models were con-
structed on a training data set that comprised 20 complete pharmacokinetic
curves from randomly assigned patients. Using this data set, the 9-AC con-
centrations at each time point (independent variable) were correlated with the
corresponding AUC (dependent variable) by univariate linear regression anal-
ysis, as assessed by Pearson’s correlation coefficient (r), to find the interval
with the optimal single-sample time point. Forward-stepwise multivariate
regression analyses were performed to include one or two additional sample
time points, if necessary. Backward-elimination regression analysis, the F-test
statistic, and the coefficient of determination were used to select the optimal
modeling strategy. The models obtained with the training data set were
validated on an independent data set composed of 12 pharmacokinetic curves
from the remaining patients. The predictive performance of the developed
models was evaluated on the basis of bias (percent mean predictive error,
%MPE) and precision (percent root mean-squared predictive error, %RMSE)
as described (Sheiner and Beal, 1981). Pearson’s correlation coefficient was
used to rank the concordance between measured and predicted pharmacoki-
netic parameters. Differences in patient demographics and pharmacokinetics
between the training and validation data sets were evaluated with the two-
tailed Student’s t test or the Fisher’s exact probability test, if required. All
statistical computations were performed with the software package Number
Cruncher Statistical System (NCSS v5.3; J.L. Hintze, Kaysville, UT, 1992)
running on an IBM-compatible computer.
Results
Thirty-two patients with various types of solid tumors were entered
in a phase I and pharmacokinetic study with 9-AC given orally.
Patients were randomly divided in a training-data set (20 patients) and
a validation-data set (12 patients) (Table 1). There were no significant
differences in baseline patient characteristics or pharmacokinetic pa-
rameters between the two cohorts (not shown). There was large
interpatient pharmacokinetic variability in the concentrations of 9-AC
at each of the sample time points, as well as with the AUC, with
values for the coefficient of variation up to 99% (see also De Jonge et
al., 1999b). The 9-AC lactone and total concentrations at each of the
sample time points were correlated with the AUC using the training-
data set by univariate regression analysis (Table 2). Overall, Pearson’s
correlation coefficients ranged from 0.241 to 0.989, with the best
correlations observed at the 3-h sample time point for both the lactone
and total forms of the drug, which was considered the most informa-
tive variable. The measured drug concentrations were subsequently
subjected to multivariate regression modeling, with a restriction to
FIG. 1. Representative plasma concentration-time profiles of 9-AC lactone ()
and 9-AC total (F) measured on day 1 of the first treatment course in a single
patient after oral administration of 9-AC at a dose level of 0.84 mg/m2 in a
daily-times fourteen schedule.
Pharmacokinetic curves were fitted to a triexponential equation using the Siphar
v4.0 computer program, assuming a three-compartment model for the distribution
and elimination of the drug.
TABLE 1
Patient demographics
Characteristic Training Set Validation Set
No. of patients 20 12
Age (years) 63 (54–74)a 55 (39–74)a
Sex (female/male) 8:12 7:5
Eastern Cooperative Oncology
Group performance status
1 (0–1)b 1 (0–2)b
Primary tumor
Ovarian 2 3
Colorectal 8 3
Pancreas 1 1
Lung (non-small cell) 1 1
Breast 1 1
Miscellaneous 7 3
a Mean value with range in parentheses.
b Median value with range in parentheses.
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models with one or two additional time points. In the bivariate
models, sample-time couples with the highest correlation and lowest
%RMSE were composed of drug concentrations at 3 h and 0.33 h, and
3 and 11 h for AUCs of the lactone and total respectively (Table 3).
Strategies for estimation of the 9-AC total AUC using more conve-
niently timed samples were all associated with significantly worse
predictive ability as compared with the modeling that included the 3-
and 11-h samples. For example, models based on inclusion of the 5-
and 7.5-h samples demonstrated correlation coefficients of only 0.969
and 0.971 with corresponding %RMSE values as high as 63.4 and
62.2%, respectively. The best models with three time points included
strategies with addition of the 11-h and 0.33-h concentration. In the
training-data set, all models demonstrated little bias with the absolute
value of the %MPE ranging from 0.10 to 0.64% of the measured AUC
(Table 3).
Concentrations of 9-AC for use in univariate and bivariate models
to predict the terminal elimination half-life showed poor correlation
coefficients (r # 0.01) combined with low accuracy (%RMSE $
46.1%) and were not used in the limited-sampling model validation.
We also considered the use of 9-AC lactone concentrations for pre-
diction of 9-AC total AUC or 9-AC carboxylate AUC, as we had
previously demonstrated a significant linear relationship (r 5 0.87)
between 9-AC lactone and 9-AC total AUCs, with the drug adminis-
tered orally at a dose level of 1.50 mg/m2 (Sparreboom et al., 1998).
In both cases, the best models included three sample time points with
acceptable correlation coefficients (up to r 5 0.91), but in the end
were rendered highly inaccurate, with values for the %RMSE ranging
from 106 to 288%.
Prospective evaluation of the proposed models was performed in
the validation-data set composed of the remaining 12 patients. In the
case of 9-AC lactone, all three models had minor bias (%MPE range:
20.71 to 20.23%) and excellent precision (%RMSE range: 6.05–
8.24%), indicating that the addition of a second and third variable did
not substantially improve the model (Table 3). Furthermore, a strong
linear correlation was observed between the measured and predicted
9-AC lactone AUCs in all models (Fig. 2A). There was some bias
noticed in the single-point model for prediction of 9-AC total AUC
with an absolute value of the %MPE of 7.8%, accompanied by a
%RMSE of $30%. Validation of the bivariate and trivariate models,
however, resulted in predictions of 9-AC total AUC that were suffi-
ciently unbiased and precise to warrant clinical application (Table 3
and Fig. 2B).
As in all validated models, computations were made without dose-
normalization. We also performed an additional analysis with the
univariate and bivariate models by including dose in milligrams per
square meter of body-surface area (mg/m2) in the AUC prediction. For
both 9-AC lactone and 9-AC total models, similar results were ob-
tained with and without dose as an additional variable, as indicated by
equivalent correlation coefficients and values for the %RMSE of 8.24
versus 8.12 and 14.5 versus 16.2, respectively, for lactone and total
forms in the two-sample models.
Discussion
In the present study we have shown that several limited-sampling
strategies can be developed for reliable and accurate prediction of the
systemic exposure to 9-AC after oral drug administration. Using
stepwise forward regression analysis, univariate and bivariate models
for independent estimation of 9-AC lactone AUC values based on one
and two sample time points, respectively, were developed and tested
for the statistical best fit. Results of models using three time points did
not show improved results in terms of bias and precision. In view of
logistical and economical reasons, the single-sample strategy is
clearly preferred to those using two samples, particularly with respect
to application in large-scale studies of population pharmacokinetics,
which require methods that are both accurate and practical in a daily
routine.
Pharmacokinetic studies with camptothecin analogs, including
9-AC, were previously shown to be complicated by a chemical,
pH-dependent instability of the terminal E-lactone ring of the com-
pounds, generating a ring-opened carboxylate, which is over 1000-
fold less active as an inhibitor of topoisomerase-I (Hertzberg et al.,
1989b). The importance of this nonenzymatic hydrolysis reaction of
the lactone moiety in the pharmacology and toxicology of 9-AC is not
yet fully understood. The clinical pharmacokinetics of the lactone and
total (i.e., lactone plus carboxylate) forms of 9-AC has been exten-
sively studied in patients receiving the drug by i.v. infusion over 72 h
(Rubin et al., 1995; Dahut et al., 1996; Takimoto et al., 1997; Eder et
al., 1998). From these studies, pharmacodynamic correlations have
been suggested between the 9-AC lactone steady-state concentration
in plasma and the degree of leukocytopenia. We have recently ob-
served similar relationships for 9-AC lactone AUC and myelotoxicity
with the drug administered orally (De Jonge et al., 1999b), which is in
line with the lactone being the pharmacological active species of the
drug. Applying a limited-sampling strategy, questions of 9-AC phar-
macodynamic outcome relating to lactone-carboxylate interconver-
sion could be answered conveniently in prospective studies. It is
noteworthy, however, that model prediction for 9-AC total AUC was
less precise than that of models for the lactone, including slight bias
in the validation-data set toward underestimation of the AUC with all
three strategies. Nevertheless, the best model for prediction of the
9-AC total AUC (including two sample time points) still can be
considered acceptable and clinically useful.
In recent years, limited-sampling strategies have also been devel-
oped for several other antineoplastic agents (reviewed in Van Warm-
erdam et al., 1994a), including the camptothecin analogs irinotecan
(CPT-11; Campto; Yamamoto et al., 1994, 1997; Sasaki et al., 1995;
Nakashima et al., 1995; Chabot, 1995; Mick et al., 1996; Mathijssen
et al., 1999) and topotecan (Hycamtin; Van Warmerdam et al., 1994b;
Minami et al., 1996). In some of these models, drug-dose levels as
measured in milligrams per square meter of body-surface area (mg/
m2) are included in the AUC estimate, by dose normalization of each
patient’s pharmacokinetic data to a constant dose. The rationale for
this procedure is to be able to discriminate between variability in dose
and interindividual variation in pharmacokinetics as the primary cause
for variability in measured concentrations. To test whether the admin-
istered dose would improve the validity of the presented models, this
parameter was also included in the single and two-sample strategies
by multivariate regression analysis. For both approaches, correlation
TABLE 2
Univariate correlation of 9-AC lactone and 9-AC total concentrations at each
sample time point with the corresponding AUC in the training-data set
Time Point 9-AC Lactone 9-AC Total
h n r n r
0.33 14 0.389 17 0.241
0.67 19 0.733 20 0.571
1.0 20 0.854 20 0.628
1.5 20 0.849 20 0.754
2.0 20 0.841 20 0.862
3.0 20 0.959 20 0.989
5.0 20 0.921 20 0.943
7.5 19 0.717 20 0.943
11 19 0.699 20 0.931
24 12 0.514 19 0.899
Abbreviation: n, number of data sets with complete pharmacokinetic curves.
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coefficients remained unchanged, whereas the %MPE and the
%RMSE in the training as well as the validation-data set of the
two-sample approach slightly decreased by an absolute maximum of
0.4%. Thus, the use of the dose in mg/m2 as an additional independent
variable did not contribute significantly to prediction of the AUC for
oral 9-AC. This conclusion is consistent with our recent observation
that oral 9-AC delineates linear and dose-independent pharmacoki-
netics within the examined dose interval, i.e., 0.25 to 1.5 mg/m2 (De
Jonge et al., 1999b).
The presented models have proven both valid and acceptable in
terms of bias and precision in a heterogeneous group of cancer
patients given 9-AC over a wide range of dose levels. Furthermore,
our current finding of extremely low intrapatient variability in oral
9-AC pharmacokinetics indicates that the models are valid also for
prediction of the AUC with repeated administration of the drug. The
clinical significance and the ultimate utility of the models, however,
remain to be explored in future studies. In addition, use of the models
in chemotherapy regimens other than the one investigated in the
current study should be done with caution, as the potential for phar-
macokinetic interactions between 9-AC and coadministered drugs,
e.g., phenytoin, phenobarbital, and/or valproic acid (Grossman et al.,
1998), cannot be ruled out.
In conclusion, the feasibility and validity of prediction of the
systemic exposure to oral 9-AC using limited-sampling strategies
were demonstrated. The optimal strategies included an univariate
model with one sample time point at 3 h for 9-AC lactone AUC and
a bivariate model with two sample time points at 3 and 11 h for 9-AC
total AUC. Application of the proposed models will be valuable in the
determination of 9-AC population pharmacokinetics and investiga-
tions of the clinical implications of the 9-AC lactone-carboxylate
interconversion with regard to pharmacodynamics. In addition, with
the strategies, routine drug monitoring is feasible, thereby allowing
treatment optimization for a given patient on the basis of individual
pharmacokinetic characteristics. This could be achieved after oral
drug administration of an appropriate starting dose of 9-AC (e.g., the
maximum tolerated dose in a 14-day schedule of 1.0 mg/m2) by
measuring the 9-AC lactone plasma concentration at 3 h after drug
dosing. Using the limited-sampling model and the linear regression
relationship between drug dose and AUC (De Jonge et al., 1999b), the
optimal dose leading to the target AUC determined according the
toxicity considered acceptable, can then be calculated.
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